GLP1R and type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled cardiovascular outcome trials assessing GLP-1 receptor agonists in patients with type 2 diabetes mellitus, including 56,004 patients with and without established cardiovascular disease, showed a 12% decrease in the primary composite endpoint regarding major adverse cardiovascular events, including cardiovascular mortality, non-fatal MI and non-fatal stroke.